New particle beam therapy targets stubborn liver tumors

NCT ID NCT07252323

Recruiting now Disease control Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a precise type of radiation called carbon ion radiotherapy for people with liver cancer that remains or comes back after a prior treatment (TARE). About 48 adults will receive this targeted radiation, with doctors tracking how well it shrinks tumors and whether side effects are manageable. The goal is to see if this approach can control the cancer while sparing healthy liver tissue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Carbon ion radiotherapy (a type of radiation therapy using carbon particles)
What this could lead to: If successful, this could offer a new, more precise radiation option for people with liver cancer that hasn't fully responded to initial treatment.
What could go wrong: This is a small, early-phase study (48 participants) with no comparison group. It's unclear if carbon ion therapy is better than other options, and radiation side effects are still possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Yonsei University Health System, Severance Hospital
RECRUITING

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.